Clinical Trial Update: A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

View source ↗

Summary

This document reports the completion of a post-marketing surveillance study of Lutathera (lutetium Lu-177 dotatate) in Korean patients with somatostatin recepto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Somatostatin Receptor-positive GEP-NET | Status: COMPLETED